Clinical Trial: Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Acneiform Eruption Due to Chemical
Study Type: INTERVENTIONAL
Official Title: A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epid
Brief Summary:
The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities.The main questions it aims to answer are:Determine the therapeutic effect of HT-001 for treatment of patients who develop acneiform rash undergoing Epidermal Growth Factor inhibitor (EGFRI) therapy using the acneiform rash investigator's global assessment scale [ARIGA]Evaluate the safety of HT-001 during treatmentParticipants will apply HT-001 Gel once per day for 6 weeks, during which…
Read more